Bio-Techne Corporation (NASDAQ: TECH) is a life sciences tools company focused on protein analysis, diagnostics, and genomics solutions. Shares recently traded around $58 per share, giving the company a market value of roughly $9.2B.
Bio-Techne operates in a specialized area of healthcare where demand is shaped by research funding levels, diagnostics adoption, and longer-term biotech innovation cycles. Looking at who owns Bio-Techne and how insiders are trading helps show how large investors may be positioning around the stock today.
Who Are Bio-Techne’s Top Shareholders?
Bio-Techne’s shareholder base is led by major institutional investors. These firms often hold through market cycles, which can help keep long-term ownership stable. Active managers adjusted positions in both directions, suggesting mixed views on valuation and near-term growth.
- The Vanguard Group: 17,893,534 shares (11.48%), ~$1.05B value. Cut 504,166 shares (-2.74%).
- BlackRock Institutional Trust Company: 8,785,755 shares (5.64%), ~$516.7M value. Cut 7,472 shares (-0.08%).
- State Street Investment Management: 5,753,393 shares (3.69%), ~$338.4M value. Cut 105,190 shares (-1.80%).
- Wellington Management Company: 5,115,133 shares (3.28%), ~$300.8M value. Added 3,978,026 shares (+349.84%).
- Atlanta Capital Management: 4,940,977 shares (3.17%), ~$290.6M value. Added 646,775 shares (+15.06%).
- Geode Capital Management: 4,927,178 shares (3.16%), ~$289.8M value. Added 864,669 shares (+21.28%).
- Invesco Capital Management: 3,513,829 shares (2.26%), ~$206.6M value. Added 275,056 shares (+8.49%).
- Neuberger Berman: 3,307,116 shares (2.12%), ~$194.5M value. Added 807,147 shares (+32.29%).
- T. Rowe Price Associates: 3,120,531 shares (2.00%), ~$183.5M value. Cut 5,495,739 shares (-63.78%).
- Maverick Capital: 3,012,654 shares (1.93%), ~$177.2M value. Built a sizable position during the period.
For investors, the mix of stable passive ownership alongside selective active buying suggests Bio-Techne continues to attract long-term institutional support, even as some managers reassess exposure following recent share price volatility.
Hedge Fund Highlights
One notable move last quarter came from Schonfeld Strategic Advisors, founded by Steven Schonfeld, which increased its Bio-Techne position by 1,334%. The firm now holds roughly $5.5M value, which may reflect growing interest following the stock’s pullback.
Ruane, Cunniff & Goldfarb, led by David Poppe, also made a sharp adjustment, boosting its stake by 867% to approximately $82M value. The increase appears to point toward longer-term conviction in Bio-Techne’s life sciences exposure rather than near-term performance.
AQR Capital Management, founded by Cliff Asness, raised its position by about 29%, bringing its holdings to just over $1M value. While smaller in size, the move stands out given AQR’s systematic investment approach.
Meanwhile, Geode Capital Management, founded by former State Street executives, increased its stake by 21% to roughly $274M value, reinforcing continued institutional support from one of Bio-Techne’s largest long-term shareholders for investors tracking conviction trends.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Bio-Techne’s Recent Insider Trades
Insider trades can offer context on how executives and directors may be managing personal exposure to the stock. Recent filings show modest sales alongside share issuances at $0, which appear tied to equity awards or vesting activity.
- James Hippel (Officer and Director): Sold ~$1.4M total; recorded shares at $0.
- Kim Kelderman (Officer and Director): Sold ~$144K at $62.57.
- William Geist (Officer): Sold ~$860K total; recorded shares at $0.
- John L. Higgins (Director): Recorded shares at $0.
- Joseph D. Keegan (Director): Recorded shares at $0.
- Robert V. Baumgartner (Director): Recorded shares at $0.
- Julie L. Bushman (Director): Recorded shares at $0.
- Rupert J. Vessey (Director): Recorded shares at $0.
These transactions do not materially change insider ownership levels, but they add context around how leadership appears to be managing equity exposure at current price levels for investors.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Bio-Techne’s shareholder base remains anchored by large institutions, which can help support long-term ownership stability. Hedge fund activity shows selective accumulation, while insider transactions appear measured and relatively small in scale.
For investors, the combined data suggests steady institutional backing, pockets of active manager optimism, and neutral insider behavior as Bio-Techne navigates a slower growth environment while maintaining exposure to long-term life sciences and diagnostics demand.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
